Pharmacyclics ( PCYC) Drug: PCI-32765 Abstract No. 8012 Indication: non-Hodgkin's lymphoma Clinical Trial: Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. Presentation Time: Saturday, June 5. Oral session. Notes: Since December, Pharmacyclics shares have gone from $2 to $7 as the company puts a history of drug development failures behind it and builds a new research pipeline.